AQST Stock - Aquestive Therapeutics, Inc.
Unlock GoAI Insights for AQST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $57.56M | $50.58M | $47.68M | $50.83M | $45.85M |
| Gross Profit | $39.69M | $29.75M | $28.29M | $35.84M | $32.88M |
| Gross Margin | 69.0% | 58.8% | 59.3% | 70.5% | 71.7% |
| Operating Income | $-30,771,000 | $-15,102,000 | $-42,066,000 | $-34,679,000 | $-42,893,000 |
| Net Income | $-44,137,000 | $-7,870,000 | $-54,410,000 | $-70,539,000 | $-55,783,000 |
| Net Margin | -76.7% | -15.6% | -114.1% | -138.8% | -121.7% |
| EPS | $-0.51 | $-0.13 | $-1.12 | $-1.85 | $-1.66 |
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 2nd 2025 | Oppenheimer | Resumed | Outperform | $7 |
| December 17th 2024 | Cantor Fitzgerald | Initiation | Overweight | $17 |
| May 10th 2024 | Leerink Partners | Initiation | Outperform | $8 |
| April 11th 2024 | Piper Sandler | Initiation | Overweight | $10 |
| March 28th 2024 | Raymond James | Initiation | Outperform | $7 |
Earnings History & Surprises
AQSTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $-0.14 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.11 | $-0.14 | -27.3% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.17 | $-0.24 | -41.2% | ✗ MISS |
Q1 2025 | Mar 5, 2025 | $-0.14 | $-0.19 | -35.7% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.11 | $-0.03 | +72.7% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.09 | $-0.17 | -88.9% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $-0.08 | $-0.12 | -50.0% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.11 | $-0.03 | +72.7% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $-0.10 | $0.11 | +210.0% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q4 2022 | Nov 1, 2022 | $-0.30 | $-0.23 | +23.3% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.41 | $-0.36 | +12.2% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $-0.45 | $-0.32 | +28.9% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $-0.37 | $-0.38 | -2.7% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $-0.40 | $-0.37 | +7.5% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-0.42 | $-0.33 | +21.4% | ✓ BEAT |
Latest News
Piper Sandler Maintains Overweight on Aquestive Therapeutics, Raises Price Target to $8
📈 PositiveAquestive Therapeutics Affirms FY2025 Sales Guidance of $44.000M-$50.000M vs $44.980M Est
➖ NeutralAquestive Therapeutics shares are trading higher after JMP Securities maintained its Market Outperform rating and raised the price target from $9 to $12.
📈 PositiveJMP Securities Maintains Market Outperform on Aquestive Therapeutics, Raises Price Target to $12
📈 PositiveAquestive Secures New Patents for Needle-Free Epinephrine Film to Treat Severe Allergies
📈 PositiveOppenheimer Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $8
📈 PositiveAquestive Therapeutics shares are trading higher after the FDA said it will not require an advisory committee meeting to discuss the New Drug Application for Anaphylm.
📈 PositiveAquestive jumps as FDA says no AdCom for allergy therapy Anaphylm
📈 PositiveFDA Skips Advisory Committee Meeting For Aquestive Therapeutics' Anaphylm; PDUFA Date Set For January 31, 2026
➖ NeutralAquestive Therapeutics rises after pricing $85M stock offering
📈 PositiveFrequently Asked Questions about AQST
What is AQST's current stock price?
What is the analyst price target for AQST?
What sector is Aquestive Therapeutics, Inc. in?
What is AQST's market cap?
Does AQST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AQST for comparison